ReviewPituitary2017
Pregnancy and acromegaly.
Review in Pituitary, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Acromegaly and pregnancy: a systematic review and meta-analysis.Pituitary · 2022Pooled it
- Safe Continuation of Pegvisomant During Pregnancy in a Patient With Fibrous Dysplasia/McCune-Albright Syndrome.JCEM case reports · 2025Article
- Acromegaly: diagnostic challenges and individualized treatment.Expert review of endocrinology & metabolism · 2025Review
- Neuroendocrine tumours and pregnancy: Real-world data from an European Neuroendocrine Tumour Centre of Excellence.Journal of neuroendocrinology · 2025Article
- Multidisciplinary Management of Pituitary Neuroendocrine Tumors During Pregnancy: Institutional Report.International journal of endocrinology · 2025Article
- Pregnancy and acromegaly: clinical outcomes of retrospectively analysed data from the German acromegaly registry.Reproductive biology and endocrinology : RB&E · 2024Article
- Surgical management of pituitary adenoma during pregnancy.World journal of clinical cases · 2023Article
- Role of Hormones During Gestation and Early Development: Pathways Involved in Developmental Programming.Advances in experimental medicine and biology · 2023Article
- Approach of Acromegaly during Pregnancy.Diagnostics (Basel, Switzerland) · 2022Review
- Placental Ischemia Says "NO" to Proper NOS-Mediated Control of Vascular Tone and Blood Pressure in Preeclampsia.International journal of molecular sciences · 2021Review
- Preconception use of pegvisomant alone or as combination therapy for acromegaly: a case series and review of the literature.Pituitary · 2020Review
- Fertility issues in aggressive pituitary tumors.Reviews in endocrine & metabolic disorders · 2020Review
- Review
- Pituitary Disease in Pregnancy: Special Aspects of Diagnosis and Treatment?Geburtshilfe und Frauenheilkunde · 2019Article
- Updates in Diagnosis and Treatment of Acromegaly.European endocrinology · 2018Review
- Functioning Endocrine Tumors in Pregnancy: Diagnostic and Therapeutic Challenges.Indian journal of endocrinology and metabolismArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAcromegaly is a rare disorder in which, due to the high incidence of secondary hypogonadism, pregnancies are relatively rare. However, some women with acromegaly do get pregnant, which brings along questions about medication, complications and follow-up. This review tries to address these issues and provide the reader with practical information.
methodsThis review summarizes published data.
conclusionsAcromegaly is a disorder that is characterized by changes in growth hormone (GH), insulin-like growth factor-1 (IGF-1) and insulin concentrations and actions. All these hormones are important in pregnancy as well. In principle, the fetal-placental collaboration between mother and child more-or-less takes over the control over GH and IGF-1, not only in normal physiology but also to a certain extend in acromegaly. When medication for the high GH levels or actions is continued during pregnancy, both dopamine agonists, somatostatin analogs and GH receptor antagonists have been used and the available data suggest that there are no adverse consequences on mother or fetus to date. However, it is strongly advised to stop any medical intervention during pregnancy until more data are available on the safety of these compounds. Also, medical treatment is not needed as tumor size and disease activity are not reported to escape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.